Brief: Ascletis Announces U.S. IND Approval Of Oral Pd-L1 Small Molecule Inhibitor Asc61 For Treatment Of Advanced Solid Tumors
06/02/2022 10:35
Feb 6 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ORAL PD-L1 SMALL
MOLECULE INHIBITOR ASC61 FOR TREATMENT OF ADVANCED SOLID TUMORS
* THE FIRST U.S. PATIENT IS EXPECTED TO BE DOSED IN THE
FIRST HALF
OF 2022
* ASC61 SHOWS SIGNIFICANT ANTITUMOR EFFICACY AS A SINGLE
AGENT IN
VARIOUS ANIMAL MODELS
Source text for Eikon: ID:nPn9GNHPma
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026